Granisetron Fresenius Kabi (Granisetron Hydrochloride)

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of acute and delayed chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) following general anesthesia.
• Adjunct therapy for patients receiving highly emetogenic cancer treatments.
• Use in combination with other antiemetic agents when single‑drug control is insufficient.

The safety profile of granisetron includes both frequently observed and rare adverse reactions.

Common

• Headache, usually mild and transient, occurring shortly after infusion.
• Constipation or reduced bowel movements, often manageable with diet or laxatives.
• Fatigue or a general feeling of weakness that resolves within 24 hours.
• Transient dizziness or light‑headedness, especially when standing quickly.

Serious

• Severe allergic reaction (anaphylaxis) presenting with rash, facial swelling, bronchospasm, or difficulty breathing, requiring immediate medical attention.
• Cardiac arrhythmia, including irregular heartbeat or palpitations, observed in patients with pre‑existing heart conditions.
• Prolonged QT interval on electrocardiogram, which may increase the risk of ventricular tachycardia or torsades de pointes.

When prescribing granisetron, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with known cardiac conduction disorders or a history of prolonged QT interval.
• Monitor electrolyte balance, especially potassium and magnesium, as abnormalities can exacerbate QT prolongation.
• Adjust dose or avoid use in severe hepatic impairment due to reduced drug clearance.
• Evaluate concomitant use of other medications that may affect cardiac rhythm.
• Consider pregnancy and lactation status; safety data are limited, and benefits must outweigh potential risks.

Granisetron may interact with other drugs; understanding these interactions helps minimize adverse effects.

Avoid

• Co‑administration with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) should be avoided.
• Use with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase granisetron plasma levels and should be avoided.

Use with caution

• Concurrent use of other serotonergic agents (e.g., ondansetron, dexamethasone) may increase the risk of serotonin syndrome; monitor patients.
• Combining with other antiemetics that have overlapping mechanisms may enhance efficacy but requires dose adjustment.
• Caution when administered with drugs that affect hepatic metabolism, such as rifampin, which may reduce granisetron exposure.
• Use cautiously in patients receiving diuretics that may cause electrolyte disturbances influencing cardiac repolarization.